Answers are grounded in this paper and cite their sources.
Cryptosporidium , a zoonotic protozoan parasite, poses a significant threat to both public health and the livestock sectors globally, leading to lethal diarrheal disease and associated economic losses. This review explores the host immune responses to Cryptosporidium spp.: infections and the prospects for vaccine development. The unique location of this parasite, "intracellular but extracytoplasmic within the parasitophorous vacuole", facilitates immune evasion and complicates host-pathogen interactions. The innate mucosal response, triggered by epithelial barriers, cytokines, and Toll-like receptors (TLRs) primes the adaptive immune response. CD4 + T cells and interferon-γ (IFN-γ) are integral in infection neutralization, with contributions from CD8 + T cells and humoral immunity. However, the disease progression and immune escaping processes, including inhibition of host signaling cascades, are not yet fully elucidated. Recent advances in vaccine development, including live-attenuated, subunit, DNA vaccines, passive immunization, or monoclonal antibodies (mAbs) have shown efficacy but face challenges due to the parasite's complex life cycle and limited in vitro culture systems. Emerging approaches, e.g., vector-based and prime-pull strategies targeting mucosal immune reactions, are optimistic about inducing strong site-specific immune responses. The prime conclusions lead to the significance of vaccines tailored to susceptible populations such as immunocompromised people and children, as well as future research directions to address the barriers to effectively preventing this protozoal parasitic disease.
No takes yet. Share an insight, caveat, or question.
Ali et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: